Abstract:Trichinella spiralis is recognized for its ability to regulate host immune responses. The serine protease inhibitor of T. spiralis ( Ts -SPI) participates in T. spiralis -mediated immunoregulatory effects. Studies have shown that helminth therapy exhibits therapeutic effects on metabolic diseases. In addition, we previously found that T. spiralis -derived crude antigens could alleviate diet-induced obesity. Thus, Ts -SPI was hypothesized to alleviate non-alcoholic fatty liver disease (NAFLD). Herein, recombinant Ts -SPI (r Ts -SPI) was prepared from the muscle larvae T. spiralis. The relative molecular mass of r Ts -SPI was approximately 35,000 Da, and western blot analysis indicated good immunoreactivity. r Ts -SPI ameliorated hepatic steatosis, inflammation, and pyroptosis in NAFLD mice, which validated the hypothesis. r Ts -SPI also reduced macrophage infiltration, significantly expanded Foxp3 + Treg population, and inactivated TLR4/NF-κB/NLRP3 signaling in the liver. Furthermore, r Ts -SPI treatment significantly shifted the gut microbiome structure, with a remarkable increase in beneficial bacteria and reduction in harmful bacteria to improve gut barrier integrity. Finally, Abx-treated mice and FMT confirmed that gut-liver crosstalk contributed to NAFLD improvement after r Ts -SPI treatment. Taken together, Taken together, these findings suggest that r Ts -SPI exerts therapeutic effects in NAFLD via anti-inflammatory activity and gut–liver crosstalk.

Serine protease inhibitor from the muscle larval Trichinella spiralis ameliorates non-alcoholic fatty liver disease in mice via anti-inflammatory properties and gut-liver crosstalk